Skip to main content
MedPathMedPath Home
Clinical Trials/ACTRN12622001074785
ACTRN12622001074785
Recruiting
N/A

The effect of positive airway pressure therapy on cardiac remodeling, cardiovascular risk factors and neurocognitive function in patients with chronic obstructive pulmonary disease and obstructive sleep apnoea overlap syndrome.

The University of Sydney0 sites20 target enrollmentAugust 3, 2022
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsChronic obstructive pulmonary diseaseObstructive sleep apnoeaCardiac remodelingCardiovascular diseaseCognitive impairmentRespiratory - Chronic obstructive pulmonary diseaseRespiratory - Sleep apnoeaCardiovascular - Other cardiovascular diseasesNeurological - Other neurological disorders

Overview

Phase
N/A
Intervention
Not specified
Conditions
Chronic obstructive pulmonary disease
Sponsor
The University of Sydney
Enrollment
20
Status
Recruiting
Last Updated
last year
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
August 3, 2022
End Date
TBD
Last Updated
last year
Study Type
Observational
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • •Participants must be aged 40 years old or older.
  • •At least 10 pack\-year smoking history.
  • •Spirometry demonstrating post bronchodilator FEV1/FVC less than the lower limits of normal (LLN) and FEV1 less than the LLN.
  • •Polysomnography (PSG) or level 2 home sleep study performed within the last 6 months of first medical visit demonstrating apnoea hypopnoea index (AHI) of equal to or greater than 30\.
  • •Patient is not already on PAP therapy and the treating physician deems patient should start PAP therapy.

Exclusion Criteria

  • •Unstable patients (COPD exacerbation within last 4 weeks or myocardial infarction or stroke within the last 6 weeks)
  • •Neuromuscular disease.
  • •Sleep disorders other than OSA.
  • •Patients who have a contraindication to or don’t tolerate CMRI or PAP therapy.
  • •Moderate or greater valvular heart disease.
  • •Renal insufficiency with eGFR\<30 ml/min/1\.73m2
  • •Unstable Malignancy.
  • •History of major psychiatric disorder in the last 12 months which is likely to affect adherence to trial protocol and follow up
  • •Willingness to provide informed consent and willingness to participate and comply with the study requirements.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Recruiting
N/A
Evaluation of the effect of the treatment with airway positive pressure device on blood pressure levels of hypertensive patients with sleep apnea syndrome.Resistant Hypertension, Obstructive Sleep Apnea SyndromeC08.618.085.852.850G47.3C14.907.489
RBR-6mbrrkFaculdade de Medicina - Universidade Federal do Rio de Janeiro
Completed
N/A
Can early treatment prevent obstructive sleep apnoea-related brain damage?Moderate obstructive sleep apnoea (between 15 and 29 hypopnoea or apnoea events per hour during sleep).Sleep apnoea-related brain damage.Neurological - Other neurological disordersRespiratory - Sleep apnoea
ACTRN12614001202651Dr. Carrie Innes45
Recruiting
N/A
Does treatment of Obstructive Sleep Apnoea in patients with Mild Cognitive Impairment improve cognition and mood?Obstructive Sleep ApnoeaMild Cognitive ImpairmentRespiratory - Sleep apnoeaMental Health - Other mental health disordersNeurological - Other neurological disorders
ACTRN12616000733471RMIT University36
Completed
N/A
CPAP treatment in stroke patients with OSADiseases of the nervous system
KCT0003688Chungnam National University Hospital80
Completed
N/A
The effect of Continuous Positive Airway Pressure (CPAP) on the collapsed lung during single-lung-ventilation in patients undergoing robot-assisted thoracoscopic esophageal resection: pulmonary complications, local and systemic cytokine productioEsophageal cancerCancerOesophageal
ISRCTN61458115niversity Medical Center Utrecht (UMCU), Department of Surgery (The Netherlands)30